JP5795630B2 - 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体 - Google Patents
抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体 Download PDFInfo
- Publication number
- JP5795630B2 JP5795630B2 JP2013508280A JP2013508280A JP5795630B2 JP 5795630 B2 JP5795630 B2 JP 5795630B2 JP 2013508280 A JP2013508280 A JP 2013508280A JP 2013508280 A JP2013508280 A JP 2013508280A JP 5795630 B2 JP5795630 B2 JP 5795630B2
- Authority
- JP
- Japan
- Prior art keywords
- fluorophenyl
- dicarboxamide
- cyclopropane
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32954810P | 2010-04-29 | 2010-04-29 | |
| US61/329,548 | 2010-04-29 | ||
| PCT/US2011/034556 WO2011137342A1 (en) | 2010-04-29 | 2011-04-29 | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525458A JP2013525458A (ja) | 2013-06-20 |
| JP2013525458A5 JP2013525458A5 (enExample) | 2014-06-19 |
| JP5795630B2 true JP5795630B2 (ja) | 2015-10-14 |
Family
ID=44260801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508280A Expired - Fee Related JP5795630B2 (ja) | 2010-04-29 | 2011-04-29 | 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20120058985A1 (enExample) |
| EP (1) | EP2563362B1 (enExample) |
| JP (1) | JP5795630B2 (enExample) |
| KR (1) | KR20130109943A (enExample) |
| CN (1) | CN103068384B (enExample) |
| AU (1) | AU2011245248B2 (enExample) |
| BR (1) | BR112012027743A2 (enExample) |
| CA (1) | CA2800569A1 (enExample) |
| DK (1) | DK2563362T3 (enExample) |
| ES (1) | ES2475741T3 (enExample) |
| IL (1) | IL222728A0 (enExample) |
| MX (1) | MX2012012571A (enExample) |
| PH (1) | PH12012502142A1 (enExample) |
| PT (1) | PT2563362E (enExample) |
| RU (1) | RU2012151012A (enExample) |
| SG (2) | SG185073A1 (enExample) |
| WO (1) | WO2011137342A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102256493A (zh) * | 2008-10-29 | 2011-11-23 | 迪赛孚尔制药有限公司 | 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物 |
| DK2563362T3 (da) * | 2010-04-29 | 2014-06-23 | Deciphera Pharmaceuticals Llc | Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet |
| CN102702120A (zh) * | 2012-04-06 | 2012-10-03 | 浙江工业大学 | 一种新化合物邻羟基苯基四嗪二甲酰胺及制备和应用 |
| CN102702121B (zh) * | 2012-04-06 | 2016-04-13 | 浙江工业大学 | 一种化合物间羟基苯基四嗪二甲酰胺及制备和应用 |
| US20150119402A1 (en) | 2012-05-08 | 2015-04-30 | The Regents Of The University Of California | Alpha 7 nicotinic acetylcholine allosteric modulators, their derivatives and uses thereof |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| EP3327144B1 (en) | 2013-02-25 | 2020-03-25 | Novartis AG | Novel androgen receptor mutation |
| WO2014145023A1 (en) * | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2016061231A1 (en) * | 2014-10-14 | 2016-04-21 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
| US20160101090A1 (en) * | 2014-10-14 | 2016-04-14 | Deciphera Pharmaceuticals, Llc | Inhibition of trk kinase mediated tumor growth and disease progression |
| US20170079966A1 (en) * | 2014-10-14 | 2017-03-23 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
| JP2019513700A (ja) | 2016-03-16 | 2019-05-30 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺有害生物剤及び植物保護剤としてのｎ−（シアノベンジル）−６−（シクロプロピル−カルボニルアミノ）−４−（フェニル）−ピリジン−２−カルボキサミド誘導体及び関連する化合物 |
| CN106349158B (zh) * | 2016-08-03 | 2020-02-28 | 杭州市西溪医院 | 一种c-Met小分子抑制剂、含其的药物组合物及其药学应用 |
| CN107793363B (zh) * | 2016-09-06 | 2021-02-26 | 上海医药工业研究院 | 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用 |
| CN106831707B (zh) * | 2016-12-28 | 2019-09-20 | 杭州市西溪医院 | 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途 |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| CN109988108B (zh) * | 2017-12-29 | 2022-04-29 | 江苏豪森药业集团有限公司 | 一种卡博替尼的制备方法 |
| AU2019216351B2 (en) | 2018-01-31 | 2024-07-25 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| EP3746059B1 (en) | 2018-01-31 | 2026-03-04 | Deciphera Pharmaceuticals, LLC | Combination therapy for the treatment of gastrointestinal stromal tumors |
| KR20210119411A (ko) | 2018-12-28 | 2021-10-05 | 데시페라 파마슈티칼스, 엘엘씨. | 암 치료에 사용하기 위한 csf1r 억제제 |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| EP3966206B1 (en) | 2019-05-10 | 2023-08-09 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| JP7626722B2 (ja) | 2019-06-17 | 2025-02-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | アミノピリミジンアミドオートファジー阻害剤およびその使用方法 |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| FI4013412T3 (fi) | 2019-08-12 | 2026-03-24 | Deciphera Pharmaceuticals Llc | Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon |
| PL4084779T3 (pl) | 2019-12-30 | 2025-02-24 | Deciphera Pharmaceuticals, Llc | Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika |
| AU2020419197B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| JP2023549540A (ja) | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法 |
| PE20250609A1 (es) | 2021-12-03 | 2025-02-26 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos |
| US12319655B2 (en) | 2021-12-09 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | RAF kinase inhibitors and methods of use thereof |
| CN114394940B (zh) * | 2022-01-26 | 2024-01-16 | 武汉工程大学 | 一种环丙基-1,1二酰胺类化合物及其制备方法和应用 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| WO2025122942A1 (en) | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Solid state forms of a kinase inhibitor |
| US20250205161A1 (en) | 2023-12-08 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| WO2025231106A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
| WO2025231105A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Processes of making csf-1r inhibitors and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1719762B1 (en) | 2004-02-27 | 2012-06-27 | Eisai R&D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (1) |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| PL1889836T3 (pl) * | 2005-08-24 | 2013-10-31 | Eisai R&D Man Co Ltd | Nowa pochodna pirydyny i pochodna pirymidyny (3) |
| AR059246A1 (es) | 2006-01-30 | 2008-03-19 | Array Biopharma Inc | Compuestos heterobiciclicos de tiofeno y metodos de uso |
| CN101454311B (zh) | 2006-08-23 | 2013-03-27 | 卫材R&D管理有限公司 | 苯氧基吡啶衍生物的盐和其结晶及其制备方法 |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| CA2679602A1 (en) | 2007-02-23 | 2008-08-28 | Eisai R&D Management Co., Ltd. | Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene |
| CN101918403A (zh) | 2007-09-06 | 2010-12-15 | 阵列生物制药公司 | 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物 |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| US20090227556A1 (en) * | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| JPWO2009104520A1 (ja) | 2008-02-18 | 2011-06-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の製造方法（２） |
| AR075084A1 (es) * | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
| CN102256493A (zh) * | 2008-10-29 | 2011-11-23 | 迪赛孚尔制药有限公司 | 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物 |
| WO2010064300A1 (ja) | 2008-12-02 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 食道癌治療用組成物 |
| JP2010178651A (ja) | 2009-02-04 | 2010-08-19 | Eisai R & D Management Co Ltd | Ｈｇｆｒ阻害物質の作用検定方法 |
| DK2563362T3 (da) * | 2010-04-29 | 2014-06-23 | Deciphera Pharmaceuticals Llc | Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet |
-
2011
- 2011-04-29 DK DK11719421.7T patent/DK2563362T3/da active
- 2011-04-29 WO PCT/US2011/034556 patent/WO2011137342A1/en not_active Ceased
- 2011-04-29 US US13/098,243 patent/US20120058985A1/en not_active Abandoned
- 2011-04-29 MX MX2012012571A patent/MX2012012571A/es active IP Right Grant
- 2011-04-29 SG SG2012079760A patent/SG185073A1/en unknown
- 2011-04-29 BR BR112012027743A patent/BR112012027743A2/pt active Search and Examination
- 2011-04-29 JP JP2013508280A patent/JP5795630B2/ja not_active Expired - Fee Related
- 2011-04-29 CN CN201180031486.XA patent/CN103068384B/zh not_active Expired - Fee Related
- 2011-04-29 KR KR1020127031316A patent/KR20130109943A/ko not_active Ceased
- 2011-04-29 EP EP11719421.7A patent/EP2563362B1/en not_active Not-in-force
- 2011-04-29 PT PT117194217T patent/PT2563362E/pt unknown
- 2011-04-29 SG SG10201503394PA patent/SG10201503394PA/en unknown
- 2011-04-29 AU AU2011245248A patent/AU2011245248B2/en not_active Ceased
- 2011-04-29 CA CA2800569A patent/CA2800569A1/en not_active Abandoned
- 2011-04-29 ES ES11719421.7T patent/ES2475741T3/es active Active
- 2011-04-29 RU RU2012151012/04A patent/RU2012151012A/ru not_active Application Discontinuation
- 2011-04-29 PH PH1/2012/502142A patent/PH12012502142A1/en unknown
-
2012
- 2012-05-24 US US13/480,108 patent/US20120252849A1/en not_active Abandoned
- 2012-07-26 US US13/559,170 patent/US8637672B2/en not_active Expired - Fee Related
- 2012-10-28 IL IL222728A patent/IL222728A0/en unknown
-
2013
- 2013-12-20 US US14/136,295 patent/US20140194405A1/en not_active Abandoned
-
2015
- 2015-01-22 US US14/602,781 patent/US20150218130A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012012571A (es) | 2013-04-05 |
| CN103068384A (zh) | 2013-04-24 |
| US20120252849A1 (en) | 2012-10-04 |
| US20120058985A1 (en) | 2012-03-08 |
| US20120322834A1 (en) | 2012-12-20 |
| HK1184392A1 (zh) | 2014-01-24 |
| EP2563362B1 (en) | 2014-03-12 |
| US20140194405A1 (en) | 2014-07-10 |
| WO2011137342A1 (en) | 2011-11-03 |
| RU2012151012A (ru) | 2014-06-10 |
| DK2563362T3 (da) | 2014-06-23 |
| US8637672B2 (en) | 2014-01-28 |
| SG185073A1 (en) | 2012-12-28 |
| CN103068384B (zh) | 2015-03-11 |
| PH12012502142A1 (en) | 2017-04-21 |
| AU2011245248B2 (en) | 2016-01-07 |
| KR20130109943A (ko) | 2013-10-08 |
| IL222728A0 (en) | 2012-12-31 |
| BR112012027743A2 (pt) | 2017-03-14 |
| JP2013525458A (ja) | 2013-06-20 |
| AU2011245248A1 (en) | 2012-12-20 |
| SG10201503394PA (en) | 2015-06-29 |
| PT2563362E (pt) | 2014-07-11 |
| EP2563362A1 (en) | 2013-03-06 |
| CA2800569A1 (en) | 2011-11-03 |
| ES2475741T3 (es) | 2014-07-11 |
| US20150218130A1 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8637672B2 (en) | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| US8921565B2 (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| US8569319B2 (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
| CN112920180A (zh) | 谷氨酰胺酶抑制剂 | |
| CA2493660A1 (en) | Process for preparing quinolin antibiotic intermediates | |
| WO2000075113A1 (en) | Novel heterocyclic carboxamide derivatives | |
| WO2021041973A1 (en) | Perk inhibiting compounds | |
| KR20220105425A (ko) | 티아졸로피리딘 또는 이의 약학적으로 허용 가능한 염 및 이의 용도 | |
| CN116903581B (zh) | Shp2/hdac双靶点抑制剂及其制备方法和应用 | |
| JP7590004B2 (ja) | 抗癌性化合物 | |
| CN111808080B (zh) | 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用 | |
| HK1184392B (en) | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP6269942B2 (ja) | ｐ３８ＭＡＰキナーゼγおよび／またはδ阻害剤 | |
| CN107474024A (zh) | 一种谷氨酰酶抑制剂及其组合物和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150223 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150522 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150615 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150714 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150813 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5795630 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |